A dock derived compound against laminin receptor (37 LR) exhibits anti-cancer properties in a prostate cancer cell line model
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1791 views | HTML 2543 views | ?
Charles Samuel Umbaugh1, Adriana Diaz-Quiñones1, Manoel Figueiredo Neto1, Joseph J. Shearer1 and Marxa L. Figueiredo1
1Department of Basic Medical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, IN 47907, USA
Marxa L. Figueiredo, email: [email protected]
Keywords: laminin receptor, drug discovery, prostate cancer, anti-cancer compound
Received: April 13, 2017 Accepted: July 16, 2017 Published: December 13, 2017
Laminin receptor (67 LR) is a 67 kDa protein derived from a 37 kDa precursor (37 LR). 37/67 LR is a strong clinical correlate for progression, aggression, and chemotherapeutic relapse of several cancers including breast, prostate, and colon. The ability of 37/67 LR to promote cancer cell aggressiveness is further increased by its ability to transduce physiochemical and mechanosensing signals in endothelial cells and modulate angiogenesis. Recently, it was demonstrated that 37/67 LR modulates the anti-angiogenic potential of the secreted glycoprotein pigment epithelium-derived factor (PEDF). Restoration of PEDF balance is a desirable therapeutic outcome, and we sought to identify a small molecule that could recapitulate known signaling properties of PEDF but without the additional complications of peptide formulation or gene delivery safety validation. We used an in silico drug discovery approach to target the interaction interface between PEDF and 37 LR. Following cell based counter screening and binding validation, we characterized a hit compound’s anti-viability, activation of PEDF signaling-related genes, anti-wound healing, and anti-cancer signaling properties. This hit compound has potential for future development as a lead compound for treating tumor growth and inhibiting angiogenesis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.